Back to results
US 2009/0269340 A1Published application
Antibodies to oncostatin m receptor
AssigneeMacroGenics, Inc.
InventorsJennie P. MATHER, Penelope E. Roberts
Life of this patent
Estimating the term…
Abstract
The invention provides characterization of the disease and cancer-associated antigen, OSM-R.beta. The invention also provides modulators of OSM-R.beta, including a family of monoclonal antibodies that bind to antigen OSM-R.beta, and methods of diagnosing and treating various human cancers and diseases associated with OSM-R.beta.
Claims24
1-15. (canceled)
16:
- A method for delivering a therapeutic agent to a cancer cell comprising administering a composition comprising an anti-OSM-R.beta antibody that specifically binds to OSM-R.beta, wherein the anti-OSM-R.beta antibody is associated with the therapeutic agent, wherein the cancer cell is selected from the group consisting of cancer cells from adrenal gland tumors, AIDS-associated cancers, alveolar soft part sarcoma, astrocytic tumors, bladder cancer (squamous cell carcinoma and transitional cell carcinoma), bone cancer (adamantinoma, aneurismal bone cysts, osteochondroma, osteosarcoma), brain and spinal cord cancers, metastatic brain tumors, breast cancer, carotid body tumors, cervical cancer, chondrosarcoma, chordoma, chromophobe renal cell carcinoma, clear cell carcinoma, colon cancer, colorectal cancer, cutaneous benign fibrous histiocytomas, desmoplastic small round cell tumors, ependymomas, Ewing's tumors, extraskeletal myxoid chondrosarcoma, fibrogenesis imperfecta ossium, fibrous dysplasia of the bone, gallbladder and bile duct cancers, gestational trophoblastic disease, germ cell tumors, head and neck cancers, islet cell tumors, Kaposi's Sarcoma, kidney cancer (nephroblastoma, papillary renal cell carcinoma), leukemias, lipomalbenign lipomatous tumors, liposarcoma/malignant lipomatous tumors, liver cancer (hepatoblastoma, hepatocellular carcinoma), lymphomas, lung cancers (small cell carcinoma, adenocarcinoma, squamous cell carcinoma, large cell carcinoma etc.), medulloblastoma, melanoma, meningiomas, multiple endocrine neoplasia, multiple myeloma, myelodysplastic syndrome, neuroblastoma, glioblastoma, neuroendocrine tumors, ovarian cancer, pancreatic cancers, papillary thyroid carcinomas, parathyroid tumors, pediatric cancers, peripheral nerve sheath tumors, phaeochromocytoma, pituitary tumors, prostate cancer, posterious unveal melanoma, rare hematologic disorders, renal metastatic cancer, rhabdoid tumor, rhabdomysarcoma, sarcomas, skin cancer, soft-tissue sarcomas, squamous cell cancer, stomach cancer, synovial sarcoma, testicular cancer, thymic carcinoma, thymoma, thyroid metastatic cancer, and uterine cancers (carcinoma of the cervix, endometrial carcinoma, and leiomyoma).
17:
- The method of claim 16, wherein the anti-OSM-R.beta antibody is the monoclonal antibody expressed by the hybridoma having ATCC No. PTA-6511, or an antigen-binding fragment thereof.
18:
- A method of inhibiting growth of cancer cells in an individual comprising administering to the individual an effective amount of a composition comprising an anti-OSM-R.beta antibody that specifically binds to OSM-R.beta to the individual, wherein the cancer cells are selected from the group consisting of cancer cells from adrenal gland tumors, AIDS-associated cancers, alveolar soft part sarcoma, astrocytic tumors, bladder cancer (squamous cell carcinoma and transitional cell carcinoma), bone cancer (adamantinoma, aneurismal bone cysts, osteochondroma, osteosarcoma), brain and spinal cord cancers, metastatic brain tumors, breast cancer, carotid body tumors, cervical cancer, chondrosarcoma, chordoma, chromophobe renal cell carcinoma, clear cell carcinoma, colon cancer, colorectal cancer, cutaneous benign fibrous histiocytomas, desmoplastic small round cell tumors, ependymomas, Ewing's tumors, extraskeletal myxoid chondrosarcoma, fibrogenesis imperfecta ossium, fibrous dysplasia of the bone, gallbladder and bile duct cancers, gestational trophoblastic disease, germ cell tumors, head and neck cancers, islet cell tumors, Kaposi's Sarcoma, kidney cancer (nephroblastoma, papillary renal cell carcinoma), leukemias, lipomalbenign lipomatous tumors, liposarcoma/malignant lipomatous tumors, liver cancer (hepatoblastoma, hepatocellular carcinoma), lymphomas, lung cancers (small cell carcinoma, adenocarcinoma, squamous cell carcinoma, large cell carcinoma etc.), medulloblastoma, melanoma, meningiomas, multiple endocrine neoplasia, multiple myeloma, myelodysplastic syndrome, neuroblastoma, glioblastoma, neuroendocrine tumors, ovarian cancer, pancreatic cancers, papillary thyroid carcinomas, parathyroid tumors, pediatric cancers, peripheral nerve sheath tumors, phaeochromocytoma, pituitary tumors, prostate cancer, posterious unveal melanoma, rare hematologic disorders, renal metastatic cancer, rhabdoid tumor, rhabdomysarcoma, sarcomas, skin cancer, soft-tissue sarcomas, squamous cell cancer, stomach cancer, synovial sarcoma, testicular cancer, thymic carcinoma, thymoma, thyroid metastatic cancer, and uterine cancers (carcinoma of the cervix, endometrial carcinoma, and leiomyoma).
19:
- The method of claim 32, wherein the therapeutic agent is delivered into the cancer cells.
20:
- The method of claim 18, wherein the anti-OSM-R.beta antibody is the monoclonal antibody expressed by the hybridoma having ATCC No. PTA-6511, or an antigen-binding fragment thereof.
21-23. (canceled)
24:
- The method of claim 16, wherein the anti-OSM-R.beta antibody comprises the three complementarity determining regions from the heavy chain and the three complementarity determining regions from the light chain of the monoclonal antibody produced by the hybridoma having ATCC No. PTA-6511.
25:
- The method of claim 24, wherein the anti-OSM-R.beta antibody is a humanized antibody.
26:
- The method of claim 24, wherein the anti-OSM-R.beta antibody is a chimeric antibody comprising the heavy chain and the light chain variable regions of the monoclonal antibody produced by the hybridoma having ATCC No. PTA-6511.
27:
- The method of claim 26, wherein the chimeric antibody comprises a heavy chain constant region and a light chain constant region from a human antibody.
28:
- The method of claim 24, wherein the anti-OSM-R.beta antibody is linked to the therapeutic agent.
29:
- The method of claim 24, wherein the anti-OSM-R.beta antibody is an antigen-binding fragment selected from the group consisting of a Fab, a Fab′, a F(ab′)2 and a Fv;
- and wherein the antigen-binding fragment retains the binding specificity of the monoclonal antibody expressed by the hybridoma having ATCC No. PTA-6511.
30:
- The method of claim 16, wherein the anti-OSM-R.beta antibody comprises the heavy chain variable region of the monoclonal antibody expressed by the hybridoma having ATCC No. PTA-6511.
31:
- The method of claim 16, wherein the anti-OSM-R.beta antibody comprises the light chain variable region of the monoclonal antibody expressed by the hybridoma having ATCC No. PTA-6511.
32:
- The method of claim 18, wherein the anti-OSM-R.beta antibody is associated with a therapeutic agent.
33:
- The method of claim 32, wherein the anti-OSM-R.beta antibody is linked to the therapeutic agent.
34:
- The method of claim 18, wherein the anti-OSM-R.beta antibody comprises the three complementarity determining regions from the heavy chain and the three complementarity determining regions from the light chain of the monoclonal antibody expressed by the hybridoma having ATCC No. PTA-6511.
35:
- The method of claim 34, wherein the anti-OSM-R.beta antibody is a humanized antibody.
36:
- The method of claim 34, wherein the anti-OSM-R.beta antibody is a chimeric antibody comprising the heavy chain and the light chain variable regions of the monoclonal antibody expressed by the hybridoma having ATCC No. PTA-6511.
37:
- The method of claim 36, wherein the chimeric antibody comprises a heavy chain constant region and a light chain constant region from a human antibody.
38:
- The method of claim 34, wherein the anti-OSM-R.beta antibody is an antigen-binding fragment selected from the group consisting of a Fab, a Fab′, a F(ab′)2 and a Fv;
- and wherein the antigen-binding fragment retains the binding specificity of the monoclonal antibody produced by the hybridoma having ATCC No. PTA-6511.
39:
- The method of claim 18, wherein the anti-OSM-R.beta antibody comprises the heavy chain variable region of the monoclonal antibody expressed by the hybridoma having ATCC No. PTA-6511.
40:
- The method of claim 18, wherein the anti-OSM-R.beta antibody comprises the light chain variable region of the monoclonal antibody expressed by the hybridoma having ATCC No. PTA-6511.